U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07566104) titled 'Group PACBT for Depression' on April 28.
Brief Summary: This study will seek to determine the (1) acceptability and (2) feasibility of psilocybin as an adjunct to cognitive-behavioral therapy, delivered as a group treatment (G-PACBT) for major depressive disorder and (3) explore the clinical effects of G-PACBT on depressive symptoms and psychosocial functioning.
Study Start Date: Jan., 2027
Study Type: INTERVENTIONAL
Condition:
Depression - Major Depressive Disorder
Psilocybin
Cognitive Behavioral Therapy
Intervention:
DRUG: Psilocybin (drug)
Two administrations of psilocybin, administered orally (a 10mg dose followed by a 25mg...